首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到16条相似文献,搜索用时 125 毫秒
1.
建立了加米霉素对照品的标定方法。采用紫外光谱、红外光谱、核磁共振波谱、质谱和X射线单晶衍射进行结构确认,高效液相色谱法进行纯度检查,质量平衡法进行定量分析,并采用定量核磁技术对赋值结果进行验证。结果显示,加米霉素对照品原料纯度为99.9%;质量平衡法赋值结果为98.8%,定量核磁共振法验证结果为98.3%。加米霉素对照品原料定量赋值结果准确、可靠,能够用于加米霉素原料及制剂的鉴别和含量测定。  相似文献   

2.
氰戊菊酯对照品的质量检测及赋值   总被引:1,自引:1,他引:0  
为研制兽用氰戊菊酯国家对照品。取氰戊菊酯原油精制得氰戊菊酯原料,经质量检查,最大紫外吸收波长为277 nm、熔点为53-54℃、水分为0.02%,用正相和反相两种高效液相色谱法测得纯度为99.8%,按质量平衡法进行含量赋值为99.8%,不确定度为±0.1%。  相似文献   

3.
按照国家对照品的研制原则研制了氰戊菊酯国家对照品。取氰戊菊酯原油精制得氰戊菊酯原料,用紫外分光光度法和高效液相色谱法对原料进行了结构确证。经质量检查,测得最大紫外吸收波长为277nm、熔点为53~54℃、水分为0.02%、炽灼残渣为0和有关物质为0.2%,用正相和反相两种高效液相色谱法测得纯度为99.8%,按质量平衡法进行含量赋值为99.8%,不确定度为?.1%。  相似文献   

4.
为了有效控制泰拉霉素原料及注射液的产品质量,研制了泰拉霉素国家对照品。采用精制后的泰拉霉素为原料进行本批对照品的研制,原料分装后进行质量检测及均匀性评价,并标定含量。采用红外分光光度法、费休氏水分测定法等对其进行理化分析,利用高效液相色谱法进行有关物质测定及均匀性检验,采用质量平衡法进行标准物质含量计算,并通过差示扫描量热法对质量平衡法的准确性进行验证。研制的泰拉霉素国家对照品的含量为98.3%,采用多种不同方法对本品进行定性与定量研究,确保了国家标准物质标定结果的准确性。本对照品可用于泰拉霉素原料及注射液的鉴别与含量测定,对于提高和保证兽药产品质量具有重要意义。  相似文献   

5.
(目的)本文旨在联合使用质量平衡法与差示扫描量热法2种定值方法测定非班太尔对照品的含量。(方法)采用高效液相色谱法测定非班太尔的纯度,采用卡尔费休氏容量滴定法、炽灼残渣检查法、气相色谱法分别测定其水分、灰分和残留溶剂,由质量平衡法公式计算非班太尔对照品的含量;采用差示扫描量热法对非班太尔对照品含量加以佐证。(结果)质量平衡法和差示扫描量热法测定结果经科克伦判定互为等精度,取其算术平均值作为最终定值结果,即非班太尔对照品含量为99.66%。(结论)质量平衡法与差示扫描量热法对非班太尔对照品的定值结果基本一致,2种方法能够更好地保证非班太尔对照品赋值的准确性。  相似文献   

6.
杨玉帅  李泽  金天明  杨升 《畜牧兽医学报》2021,52(10):2924-2933
旨在提高烯丙孕素原药在水中的溶解度,提高烯丙孕素原药的生物利用度,使用磺丁基-β-环糊精对烯丙孕素原药进行包合。本试验使用冷冻干燥法来制备烯丙孕素-磺丁基-β-环糊精包合物,以此来解决烯丙孕素在临床使用中因其水不溶性而受到限制及其使用后生物利用度低的问题,进而拓宽烯丙孕素的药用途径。通过傅里叶变换红外光谱法、热重分析法和显微镜成像法对所制得的烯丙孕素包合物进行表征,并用溶解度法对包合物进行溶解度测定。以包合物的收率和包合率为评价指标,筛选最优的包合物制备条件。结果显示:经筛选,包合物的最佳制备条件:在55℃,ALT与SBE-β-CD的投料摩尔比为1:6,包合时间为5 h,溶液pH为8,溶剂量为15 mL(当以ALT投药量为0.1 g时计);以最优制备条件制备所得的包合物中ALT的平均包合率为(90.90±1.80)%(n=3),平均载药量为(4.30±2.30)%(n=3),包合物的收率为(93.19±1.67)%。经傅里叶变换红外光谱法、热重分析法和显微镜成像法对所制得的包合物进行表征,可证实成功制得包合物。溶解度法试验结果表明,形成包合物后,其溶解度较烯丙孕素原药提高了988.86倍,且该包合物稳定性好,可满足不同剂型的要求。磺丁基-β-环糊精对烯丙孕素原药具有较好的增溶作用,达到了增加药物溶解度的目的,且该制备方法简单,条件温和,易于产业化生产,有利于烯丙孕素的进一步开发利用。  相似文献   

7.
为了研制甲苯咪唑国家对照品,采用精制后的甲苯咪唑为原料,并进行质量评价。采用紫外分光光度法、红外分光光度法对原料进行鉴别,采用质量平衡法定值,同时采用容量法和高效液相色谱法加以佐证。结果显示,紫外吸收图谱与标准规定一致、红外光吸收图谱与USP溯源对照品图谱一致;以质量平衡法计算其含量为99.8%,容量法测定含量为99.9%,液相色谱外标法测定含量为99.9%,三种方法测定结果一致。本次研制的甲苯咪唑对照品可用于甲苯咪唑及其制剂的鉴别与含量测定。  相似文献   

8.
建立了烯丙孕素口服液中烯丙孕素含量测定的高效液相色谱分析方法及样品前处理方法。采用正相高效液相色谱法,前处理溶剂为异丙醇-正己烷(5:20),色谱柱为ZORBAX CN C18柱(250×4.0 mm,5μm),流动相正己烷-异丙醇(98:2),流速1.0 mL/min,柱温35℃,检测波长235 nm。该方法中烯丙孕素的定量限浓度为804.9 ng/mL,线性范围为0.401~0.601 mg/mL,平均回收率为100.3%,该方法前处理简单、准确度高,可适用于该制剂中烯丙孕素的定性定量测定。  相似文献   

9.
研究烯丙孕素-β-环糊精包合物以及烯丙孕素-羟丙基-β-环糊精包合物制备工艺。采用正交试验法优选β-环糊精以及羟丙基-β-环糊精对烯丙孕素的包合工艺。选用圆二色谱法对包合物进行表征,并考察包合物的稳定性。以包合物中收率和包合率为指标,筛选出最佳包合条件为烯丙孕素与β-环糊精投料摩尔比为1∶3,65℃加热搅拌3 h;烯丙孕素与羟丙基-β-环糊精投料摩尔比为1∶6,55℃加热搅拌4 h。经圆二色谱法鉴定,已经形成包合物,并且具有一定稳定性。试验得出的制备工艺稳定可行。  相似文献   

10.
本研究旨在分析烯丙孕素在猪体内的残留消除规律,为制定休药期提供依据。采集猪肝、肾、肌肉和脂肪样品,肝、肾样品经β-葡萄糖醛酸酶/芳基硫酸酯酶酶解,然后用乙腈提取(肌肉和脂肪样品直接用乙腈提取),乙腈饱和正己烷溶液除脂,氮吹后残渣用乙酸乙酯复溶,后用10%碳酸钠溶液净化进行LC-MS/MS分析,外标法定量。结果表明:在1~200ng·mL~(-1)浓度范围内,烯丙孕素具有良好的线性关系,相关系数大于0.999,方法的检测限为0.5μg·kg~(-1),定量限为1μg·kg~(-1);在1、100、200μg·kg~(-1)添加水平下,化合物的平均回收率在68.9%~78.9%,相对标准偏差均小于11%。试验猪按0.4mg·kg~(-1)剂量内服给药,每天1次,连续给药18d,经取材检测,休药6h后各组织中烯丙孕素残留量最高,休药后第5天脂肪中烯丙孕素残留量低于最大残留限量,肌肉、肾中残留量低于定量限,休药第10天所有组织中烯丙孕素残留量均低于定量限。休药后相同时间点猪组织中烯丙孕素残留量规律为肝肾脂肪肌肉;肝中烯丙孕素消除缓慢且消除时间最长。根据WT1.4软件按99%置信区间计算所得,建议母猪按0.4mg·kg~(-1)剂量内服给药,每天1次,连续18d,其休药期为9d。  相似文献   

11.
以乙酰氨基阿维菌素为原料研制首批乙酰氨基阿维菌素国家对照品,并进行质量评价。采用高效液相色谱法和质谱法对原料进行结构确证,分装后的乙酰氨基阿维菌素对照品采用质量平衡法定值,同时采用高效液相色谱外标法加以佐证。结果显示,以质量平衡法计算乙酰氨基阿维菌素(B1a+B1b)含量为97.79%,液相色谱外标法测定含量为98.18%,两种方法测定结果基本一致。本次研制的乙酰氨基阿维菌素对照品可用于乙酰氨基阿维菌素及其制剂的鉴别与含量测定。  相似文献   

12.
国家那西肽标准品的研制与建立   总被引:1,自引:1,他引:0       下载免费PDF全文
本文介绍了首批国家那西肽标准品的研制与建立方法。那西肽标准品为黄绿色粉末,质谱法测定分子量为1220.15,用两种高效液相色谱法测定平均纯度为94.26%,干燥失重和炽灼残渣的结果为3.97%和2.00%,用质量平衡法定值含量为928u/mg。  相似文献   

13.
为了研制匹莫苯丹对照品,采用精制后的匹莫苯丹为原料,并进行质量评价。采用熔点法、红外分光光度法、液相色谱法对原料进行鉴别,采用质量平衡法定值,同时采用容量法和高效液相色谱法加以佐证。结果显示,以质量平衡法计算其含量为99.8%,容量法测定含量为99.7%,液相色谱外标法测定含量为99.6%,三种方法测定结果一致。本次研制的匹莫苯丹对照品可用于匹莫苯丹及其制剂的鉴别与含量测定。  相似文献   

14.
Endogenous progesterone levels may decline after transcervical embryo transfer in some mares. Progestogen therapy is commonly used to support endogenous progesterone levels in embryo transfer recipient mares or those carrying their own pregnancy. The goal of this study was to determine the effects of the transcervical transfer procedure and/or altrenogest therapy on luteal function in mares. Mares were assigned to one of six treatment groups: group 1 (untreated control; n = 7 cycles), group 2 (sham transfer, no altrenogest; n = 8 cycles), group 3 (sham transfer plus altrenogest; n = 8 cycles), group 4 (pregnant, no altrenogest; n = 9 mares), group 5 (pregnant plus altrenogest; n = 9 mares), and group 6 (nonpregnant plus altrenogest; n = 10 cycles). Mares in groups 4-6 were bred and allowed an opportunity to carry their own pregnancy. Blood samples were collected for 22 days beginning on the day of ovulation. Sham embryo transfer (groups 2 and 3, combined) did not result in a decline in endogenous progesterone levels compared with control mares (group 6). However, sham embryo transfer did result in luteolysis and an abrupt decline in endogenous progesterone levels in one of the 16 (6.2%) sham-transferred mares. Altrenogest therapy in sham-transferred mares (group 3) was associated with lower endogenous progesterone levels on days 10, 12, and 13 postovulation when compared with sham-transferred mares that did not receive altrenogest (group 2). Administration of altrenogest to pregnant mares (group 5) was associated with lower concentrations of endogenous progesterone from days 14 to 18 and on day 21 compared with endogenous progesterone levels in pregnant mares not administered altrenogest (group 4). In conclusion, a transcervical embryo transfer procedure can cause luteolysis in a low percentage of mares. Altrenogest therapy may be associated with a reduction in endogenous progesterone secretion, presumably mediated by a reduction in pituitary luteinizing hormone (LH) release and a decrease in luteotropic support.  相似文献   

15.
建立了药物盐酸阿苯达唑亚砜的化学结构确证方法.通过高效液相色谱(HPLC)测定盐酸阿苯达唑亚砜纯度,采用紫外光谱(UV)、红外光谱(IR)、核磁共振(NMR)以及质谱(MS)等分析方法对盐酸阿苯达唑亚砜样品进行了结构测定.结果确证盐酸阿苯达唑亚砜的结构为[5-(丙亚砜基)-1H-苯并咪唑-2-基]氨基甲酸甲醋盐酸.本方...  相似文献   

16.
Lactating mares were assigned as controls or fed altrenogest (.044 mg.kg body wt-1.d-1) for 15 d after foaling. Mares (n = 6) fed altrenogest were inseminated during the first estrus after treatment and mares (n = 6) in the control group were inseminated during the second postpartum estrus. Ovulation during the estrus in which mares were inseminated occurred 26 +/- 1 d postpartum for treated mares and 36 +/- 1 d postpartum for control mares. The percentage of mares conceiving was not different for control (67%) and alternogest-treated (100%) mares. No differences were observed in tone and size of the uterus or size of the ovulatory follicle between treated and control groups. Uterine cultures and biopsies collected on d 7 and 15 postpartum were similar between treatment and control groups in bacterial populations or endometrial epithelial cell height. Blood was collected on d 7, 11, 15, 19 and 23 postpartum, and concentrations of estradiol-17 beta in serum were determined by radioimmunoassay. Mean concentrations of estradiol-17 beta across days were 10 +/- .8 and 12 +/- .6 pg/ml for control and treated mares, respectively. Concentrations of serum estradiol-17 beta were higher (P less than .05) in treated mares on d 23 postpartum. Daily milk yields, determined by the weigh-suckle-weigh method, and milk composition were similar between treatment groups on each collection day. Altrenogest can be used to predictably delay estrus in the postpartum mare without altering fertility, yield and composition of milk, or foal growth.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号